Paul Dekker
Hematology & Oncology · Hartford, CTNPI 1497850614
Payments from drug & device makers
Across 313 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$756
- Johnson & Johnson$716
- Genentech USA, Inc.$548
- Incyte Corporation$349
- E.r. Squibb & Sons, L.L.C.$316
- Bristol Myers Squibb$277
- plus $3K from 35 others
What the payments were for
- Speaking & faculty fees$1252%
- Food & beverage$5,21590%
- Education$4788%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 46 | $756 |
| Johnson & Johnson(2 entities) | 40 | $716 |
| Genentech USA, Inc. | 28 | $548 |
| Incyte Corporation | 14 | $349 |
| E.r. Squibb & Sons, L.L.C. | 18 | $316 |
| Bristol Myers Squibb | 15 | $277 |
| Pfizer | 10 | $263 |
| Merck | 19 | $263 |
| Seagen Inc. | 10 | $184 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $173 |
| Gilead(2 entities) | 9 | $160 |
| AbbVie | 6 | $141 |
| Epizyme, Inc. | 6 | $125 |
| Bayer | 6 | $125 |
| Amgen | 9 | $125 |
| AstraZeneca | 7 | $119 |
| Lilly USA, LLC | 7 | $113 |
| Sanofi | 6 | $101 |
| Jazz Pharmaceuticals Inc. | 4 | $86 |
| AMAG Pharmaceuticals, Inc. | 5 | $83 |
| Astellas Pharma US Inc | 3 | $77 |
| Exelixis Inc. | 3 | $77 |
| Boehringer Ingelheim | 4 | $75 |
| Array Biopharma Inc | 3 | $67 |
| Rigel Pharmaceuticals, Inc. | 3 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $50 |
| Karyopharm Therapeutics Inc. | 3 | $49 |
| Beigene USA, Inc. | 2 | $47 |
| Kyowa Kirin, Inc. | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Helsinn Therapeutics (U.S.), Inc. | 2 | $27 |
| EMD Serono, Inc. | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Verastem, Inc. | 1 | $20 |
| Advanced Accelerator Applications | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Clovis Oncology, Inc. | 1 | $13 |
| Aurobindo Pharma USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,818 in reported general payments places this provider in the 45th percentile of 163 hematology & oncology providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 11 | $14,171 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 33 | $886 |
| Atorvastatin Calcium | 110 | $816 |
| Omeprazole | 19 | $535 |
| Lisinopril | 25 | $372 |
| Amlodipine Besylate | 40 | $311 |
| Levothyroxine Sodium | 28 | $298 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $201 |
| Losartan Potassium | 18 | $194 |
| Metformin Hcl | 35 | $194 |
| Metoprolol Succinate | 17 | $179 |
| Simvastatin | 23 | $174 |
| Ezetimibe | 13 | $154 |
| Rosuvastatin Calcium | 12 | $147 |
| Pantoprazole Sodium | 17 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $263 | $14,17111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 163 hematology & oncology providers in Connecticut.
Other hematology & oncology in Hartford
- Jeffrey KamradtHartford$934K
- Jessica ClementHartford$887K
- Zia RahmanHartford$307K
- Madhavi GorusuHartford$207K
- Todd AlekshunHartford$115K
- Adam BoruchovHartford$55K
- Shabnam RehmanHartford$25K
- Amer ZeidanNew Haven$15.5M
- Nataliya UbohaNew Haven$13.3M
- Michael CecchiniNew Haven$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.